Voyager Therapeutics (VYGR) Total Liabilities (2016 - 2025)
Historic Total Liabilities for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $68.5 million.
- Voyager Therapeutics' Total Liabilities fell 2846.0% to $68.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.5 million, marking a year-over-year decrease of 2846.0%. This contributed to the annual value of $93.3 million for FY2024, which is 1885.07% down from last year.
- Voyager Therapeutics' Total Liabilities amounted to $68.5 million in Q3 2025, which was down 2846.0% from $78.2 million recorded in Q2 2025.
- Voyager Therapeutics' Total Liabilities' 5-year high stood at $148.3 million during Q1 2022, with a 5-year trough of $68.5 million in Q3 2025.
- Over the past 5 years, Voyager Therapeutics' median Total Liabilities value was $100.8 million (recorded in 2024), while the average stood at $104.8 million.
- As far as peak fluctuations go, Voyager Therapeutics' Total Liabilities tumbled by 5820.15% in 2021, and later skyrocketed by 4604.71% in 2022.
- Quarter analysis of 5 years shows Voyager Therapeutics' Total Liabilities stood at $98.8 million in 2021, then increased by 1.55% to $100.3 million in 2022, then grew by 14.58% to $115.0 million in 2023, then fell by 18.85% to $93.3 million in 2024, then fell by 26.59% to $68.5 million in 2025.
- Its Total Liabilities stands at $68.5 million for Q3 2025, versus $78.2 million for Q2 2025 and $80.5 million for Q1 2025.